Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.
Also called NCT02066662
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose basic science
- Phase
- Phase 4
- Enrolled
- 192 participants
- Sponsor
- Registry
-
NCT02066662
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT02066662. Randomized; single masking; primary purpose basic science. Start 2013-07 (registry gives no type); primary completion 2020-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
- Condition
- Atrial Fibrillation or Pulmonary Embolism
- Condition
- Need of Long Term Oral Anticoagulation Therapy (OAT)
- Condition
- Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
- Intervention (Drug)
- Rivaroxaban or Marcumar
- Lead sponsor
- RWTH Aachen University
- Collaborator
- Bayer
Record details
- Record id
cardio:ct-nct02066662- Content hash
ad7deb9a9ce07874955dc5e05109b3289f8f22e0b8ffd6a512fae10a7b53ae06